nodes	percent_of_prediction	percent_of_DWPC	metapath
Granisetron—CYP3A4—Thiotepa—urinary bladder cancer	0.0674	0.41	CbGbCtD
Granisetron—CYP3A5—Etoposide—urinary bladder cancer	0.0469	0.285	CbGbCtD
Granisetron—CYP2D6—Doxorubicin—urinary bladder cancer	0.0196	0.119	CbGbCtD
Granisetron—CYP3A4—Etoposide—urinary bladder cancer	0.0183	0.111	CbGbCtD
Granisetron—CYP3A4—Doxorubicin—urinary bladder cancer	0.0125	0.0757	CbGbCtD
Granisetron—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.00235	0.0121	CbGpPWpGaD
Granisetron—CYP3A5—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.00232	0.012	CbGpPWpGaD
Granisetron—CYP3A4—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.00228	0.0118	CbGpPWpGaD
Granisetron—CYP1A1—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.00222	0.0115	CbGpPWpGaD
Granisetron—CYP1A1—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.00219	0.0113	CbGpPWpGaD
Granisetron—CYP3A4—Aflatoxin B1 metabolism—GSTM1—urinary bladder cancer	0.002	0.0103	CbGpPWpGaD
Granisetron—CYP1A1—Estrogen Receptor Pathway—ESR1—urinary bladder cancer	0.00195	0.01	CbGpPWpGaD
Granisetron—CYP1A1—Estrogen metabolism—GSTM1—urinary bladder cancer	0.00191	0.00986	CbGpPWpGaD
Granisetron—CYP3A5—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.0019	0.00983	CbGpPWpGaD
Granisetron—CYP3A5—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.0019	0.00979	CbGpPWpGaD
Granisetron—CYP1A1—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.0018	0.00928	CbGpPWpGaD
Granisetron—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.00172	0.00888	CbGpPWpGaD
Granisetron—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.00167	0.00862	CbGpPWpGaD
Granisetron—CYP1A1—Oxidative Stress—NQO1—urinary bladder cancer	0.00166	0.00855	CbGpPWpGaD
Granisetron—CYP2D6—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.00165	0.00851	CbGpPWpGaD
Granisetron—HTR3A—SIDS Susceptibility Pathways—ESR2—urinary bladder cancer	0.00149	0.00767	CbGpPWpGaD
Granisetron—CYP1A1—Aryl Hydrocarbon Receptor—HPGDS—urinary bladder cancer	0.00146	0.00753	CbGpPWpGaD
Granisetron—HTR3A—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.00143	0.00739	CbGpPWpGaD
Granisetron—CYP1A1—Arachidonic acid metabolism—HPGDS—urinary bladder cancer	0.00136	0.00705	CbGpPWpGaD
Granisetron—CYP2D6—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.00135	0.00699	CbGpPWpGaD
Granisetron—CYP3A5—Biological oxidations—GSTZ1—urinary bladder cancer	0.00129	0.00669	CbGpPWpGaD
Granisetron—CYP3A5—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.00128	0.0066	CbGpPWpGaD
Granisetron—CYP1A1—Oxidative Stress—SOD2—urinary bladder cancer	0.00127	0.00658	CbGpPWpGaD
Granisetron—CYP3A5—Biological oxidations—NAT1—urinary bladder cancer	0.00123	0.00634	CbGpPWpGaD
Granisetron—CYP3A5—Biological oxidations—GSTO2—urinary bladder cancer	0.00123	0.00634	CbGpPWpGaD
Granisetron—CYP3A4—Estrogen metabolism—NQO1—urinary bladder cancer	0.00123	0.00633	CbGpPWpGaD
Granisetron—CYP1A1—Biological oxidations—GSTZ1—urinary bladder cancer	0.00122	0.00632	CbGpPWpGaD
Granisetron—CYP1A1—Oxidative Stress—GPX1—urinary bladder cancer	0.00122	0.00628	CbGpPWpGaD
Granisetron—CYP3A5—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.00121	0.00625	CbGpPWpGaD
Granisetron—CYP1A1—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.00121	0.00623	CbGpPWpGaD
Granisetron—CYP1A1—Aryl Hydrocarbon Receptor—NQO1—urinary bladder cancer	0.00118	0.00607	CbGpPWpGaD
Granisetron—CYP1A1—Aryl Hydrocarbon Receptor Pathway—NQO1—urinary bladder cancer	0.00118	0.00607	CbGpPWpGaD
Granisetron—CYP1A1—Biological oxidations—GSTO2—urinary bladder cancer	0.00116	0.00599	CbGpPWpGaD
Granisetron—CYP1A1—Biological oxidations—NAT1—urinary bladder cancer	0.00116	0.00599	CbGpPWpGaD
Granisetron—CYP1A1—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.00114	0.00591	CbGpPWpGaD
Granisetron—CYP3A5—Biological oxidations—UGT2B7—urinary bladder cancer	0.00112	0.0058	CbGpPWpGaD
Granisetron—CYP3A5—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.00111	0.00572	CbGpPWpGaD
Granisetron—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.00109	0.00564	CbGpPWpGaD
Granisetron—CYP3A4—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.00108	0.00556	CbGpPWpGaD
Granisetron—CYP1A1—Biological oxidations—UGT2B7—urinary bladder cancer	0.00106	0.00548	CbGpPWpGaD
Granisetron—CYP1A1—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.00105	0.0054	CbGpPWpGaD
Granisetron—HTR3A—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.00103	0.00534	CbGpPWpGaD
Granisetron—CYP3A5—Biological oxidations—CYP4B1—urinary bladder cancer	0.00101	0.00522	CbGpPWpGaD
Granisetron—CYP3A5—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000997	0.00515	CbGpPWpGaD
Granisetron—CYP1A1—Biological oxidations—CYP4B1—urinary bladder cancer	0.000955	0.00493	CbGpPWpGaD
Granisetron—CYP1A1—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000942	0.00486	CbGpPWpGaD
Granisetron—CYP3A4—Estrogen metabolism—GSTM1—urinary bladder cancer	0.00094	0.00485	CbGpPWpGaD
Granisetron—CYP2D6—Biological oxidations—GSTZ1—urinary bladder cancer	0.000921	0.00475	CbGpPWpGaD
Granisetron—CYP2D6—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000908	0.00469	CbGpPWpGaD
Granisetron—CYP3A4—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000885	0.00457	CbGpPWpGaD
Granisetron—CYP3A4—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.000881	0.00455	CbGpPWpGaD
Granisetron—CYP2D6—Biological oxidations—NAT1—urinary bladder cancer	0.000873	0.00451	CbGpPWpGaD
Granisetron—CYP2D6—Biological oxidations—GSTO2—urinary bladder cancer	0.000873	0.00451	CbGpPWpGaD
Granisetron—CYP2D6—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000861	0.00445	CbGpPWpGaD
Granisetron—HTR3A—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.000843	0.00436	CbGpPWpGaD
Granisetron—CYP1A1—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.000808	0.00417	CbGpPWpGaD
Granisetron—CYP2D6—Biological oxidations—UGT2B7—urinary bladder cancer	0.000798	0.00412	CbGpPWpGaD
Granisetron—HTR3A—SIDS Susceptibility Pathways—CREBBP—urinary bladder cancer	0.00079	0.00408	CbGpPWpGaD
Granisetron—CYP2D6—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000787	0.00407	CbGpPWpGaD
Granisetron—Photosensitivity reaction—Epirubicin—urinary bladder cancer	0.000766	0.00119	CcSEcCtD
Granisetron—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000766	0.00119	CcSEcCtD
Granisetron—Paraesthesia—Etoposide—urinary bladder cancer	0.000764	0.00119	CcSEcCtD
Granisetron—Dyspnoea—Etoposide—urinary bladder cancer	0.000759	0.00118	CcSEcCtD
Granisetron—Somnolence—Etoposide—urinary bladder cancer	0.000757	0.00118	CcSEcCtD
Granisetron—Angina pectoris—Doxorubicin—urinary bladder cancer	0.000756	0.00118	CcSEcCtD
Granisetron—Hepatobiliary disease—Methotrexate—urinary bladder cancer	0.000756	0.00118	CcSEcCtD
Granisetron—Epistaxis—Methotrexate—urinary bladder cancer	0.000754	0.00117	CcSEcCtD
Granisetron—Vomiting—Thiotepa—urinary bladder cancer	0.000753	0.00117	CcSEcCtD
Granisetron—Rash—Thiotepa—urinary bladder cancer	0.000747	0.00116	CcSEcCtD
Granisetron—Dermatitis—Thiotepa—urinary bladder cancer	0.000746	0.00116	CcSEcCtD
Granisetron—Headache—Thiotepa—urinary bladder cancer	0.000742	0.00116	CcSEcCtD
Granisetron—Decreased appetite—Etoposide—urinary bladder cancer	0.00074	0.00115	CcSEcCtD
Granisetron—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000735	0.00115	CcSEcCtD
Granisetron—Body temperature increased—Cisplatin—urinary bladder cancer	0.000734	0.00114	CcSEcCtD
Granisetron—Jaundice—Epirubicin—urinary bladder cancer	0.000729	0.00114	CcSEcCtD
Granisetron—Constipation—Etoposide—urinary bladder cancer	0.000728	0.00113	CcSEcCtD
Granisetron—Pain—Etoposide—urinary bladder cancer	0.000728	0.00113	CcSEcCtD
Granisetron—Urinary tract infection—Epirubicin—urinary bladder cancer	0.000727	0.00113	CcSEcCtD
Granisetron—Dysuria—Doxorubicin—urinary bladder cancer	0.000726	0.00113	CcSEcCtD
Granisetron—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000722	0.00113	CcSEcCtD
Granisetron—CYP2D6—Biological oxidations—CYP4B1—urinary bladder cancer	0.000719	0.00371	CbGpPWpGaD
Granisetron—Sweating—Epirubicin—urinary bladder cancer	0.000717	0.00112	CcSEcCtD
Granisetron—Asthenia—Gemcitabine—urinary bladder cancer	0.000715	0.00111	CcSEcCtD
Granisetron—CYP2D6—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000709	0.00366	CbGpPWpGaD
Granisetron—Photosensitivity reaction—Doxorubicin—urinary bladder cancer	0.000709	0.0011	CcSEcCtD
Granisetron—CYP1A1—Aryl Hydrocarbon Receptor—ESR1—urinary bladder cancer	0.000708	0.00366	CbGpPWpGaD
Granisetron—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.000708	0.0011	CcSEcCtD
Granisetron—Epistaxis—Epirubicin—urinary bladder cancer	0.000706	0.0011	CcSEcCtD
Granisetron—Pruritus—Gemcitabine—urinary bladder cancer	0.000705	0.0011	CcSEcCtD
Granisetron—Nausea—Thiotepa—urinary bladder cancer	0.000704	0.0011	CcSEcCtD
Granisetron—Sinusitis—Epirubicin—urinary bladder cancer	0.000702	0.00109	CcSEcCtD
Granisetron—Feeling abnormal—Etoposide—urinary bladder cancer	0.000701	0.00109	CcSEcCtD
Granisetron—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000696	0.00108	CcSEcCtD
Granisetron—Pruritus—Fluorouracil—urinary bladder cancer	0.000693	0.00108	CcSEcCtD
Granisetron—Visual impairment—Methotrexate—urinary bladder cancer	0.000692	0.00108	CcSEcCtD
Granisetron—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000685	0.00107	CcSEcCtD
Granisetron—Bradycardia—Epirubicin—urinary bladder cancer	0.000684	0.00107	CcSEcCtD
Granisetron—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000682	0.00106	CcSEcCtD
Granisetron—Urticaria—Etoposide—urinary bladder cancer	0.000676	0.00105	CcSEcCtD
Granisetron—Jaundice—Doxorubicin—urinary bladder cancer	0.000675	0.00105	CcSEcCtD
Granisetron—Rhinitis—Epirubicin—urinary bladder cancer	0.000673	0.00105	CcSEcCtD
Granisetron—Abdominal pain—Etoposide—urinary bladder cancer	0.000673	0.00105	CcSEcCtD
Granisetron—Body temperature increased—Etoposide—urinary bladder cancer	0.000673	0.00105	CcSEcCtD
Granisetron—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000673	0.00105	CcSEcCtD
Granisetron—CYP3A5—Biological oxidations—NAT2—urinary bladder cancer	0.000673	0.00347	CbGpPWpGaD
Granisetron—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000671	0.00104	CcSEcCtD
Granisetron—Asthenia—Cisplatin—urinary bladder cancer	0.000667	0.00104	CcSEcCtD
Granisetron—Sweating—Doxorubicin—urinary bladder cancer	0.000664	0.00103	CcSEcCtD
Granisetron—CYP3A5—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000663	0.00343	CbGpPWpGaD
Granisetron—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.00066	0.00103	CcSEcCtD
Granisetron—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.000655	0.00102	CcSEcCtD
Granisetron—Epistaxis—Doxorubicin—urinary bladder cancer	0.000653	0.00102	CcSEcCtD
Granisetron—Angiopathy—Methotrexate—urinary bladder cancer	0.000651	0.00101	CcSEcCtD
Granisetron—Sinusitis—Doxorubicin—urinary bladder cancer	0.000649	0.00101	CcSEcCtD
Granisetron—Dizziness—Fluorouracil—urinary bladder cancer	0.000648	0.00101	CcSEcCtD
Granisetron—Visual impairment—Epirubicin—urinary bladder cancer	0.000647	0.00101	CcSEcCtD
Granisetron—Chills—Methotrexate—urinary bladder cancer	0.000644	0.001	CcSEcCtD
Granisetron—Diarrhoea—Cisplatin—urinary bladder cancer	0.000636	0.000991	CcSEcCtD
Granisetron—CYP1A1—Biological oxidations—NAT2—urinary bladder cancer	0.000635	0.00328	CbGpPWpGaD
Granisetron—Alopecia—Methotrexate—urinary bladder cancer	0.000634	0.000988	CcSEcCtD
Granisetron—Vomiting—Gemcitabine—urinary bladder cancer	0.000634	0.000988	CcSEcCtD
Granisetron—Bradycardia—Doxorubicin—urinary bladder cancer	0.000633	0.000986	CcSEcCtD
Granisetron—Rash—Gemcitabine—urinary bladder cancer	0.000628	0.000979	CcSEcCtD
Granisetron—Dermatitis—Gemcitabine—urinary bladder cancer	0.000628	0.000978	CcSEcCtD
Granisetron—Hypersensitivity—Etoposide—urinary bladder cancer	0.000627	0.000977	CcSEcCtD
Granisetron—HTR3A—SIDS Susceptibility Pathways—CXCL8—urinary bladder cancer	0.000627	0.00324	CbGpPWpGaD
Granisetron—CYP1A1—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000627	0.00324	CbGpPWpGaD
Granisetron—Malnutrition—Methotrexate—urinary bladder cancer	0.000625	0.000973	CcSEcCtD
Granisetron—Headache—Gemcitabine—urinary bladder cancer	0.000624	0.000973	CcSEcCtD
Granisetron—Flushing—Epirubicin—urinary bladder cancer	0.000623	0.000971	CcSEcCtD
Granisetron—Vomiting—Fluorouracil—urinary bladder cancer	0.000623	0.000971	CcSEcCtD
Granisetron—Rhinitis—Doxorubicin—urinary bladder cancer	0.000623	0.000971	CcSEcCtD
Granisetron—CYP1A1—Aryl Hydrocarbon Receptor—RB1—urinary bladder cancer	0.000618	0.00319	CbGpPWpGaD
Granisetron—Rash—Fluorouracil—urinary bladder cancer	0.000618	0.000963	CcSEcCtD
Granisetron—Dermatitis—Fluorouracil—urinary bladder cancer	0.000617	0.000962	CcSEcCtD
Granisetron—Headache—Fluorouracil—urinary bladder cancer	0.000614	0.000957	CcSEcCtD
Granisetron—Dysgeusia—Methotrexate—urinary bladder cancer	0.000612	0.000953	CcSEcCtD
Granisetron—Asthenia—Etoposide—urinary bladder cancer	0.000611	0.000952	CcSEcCtD
Granisetron—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000611	0.000951	CcSEcCtD
Granisetron—Angiopathy—Epirubicin—urinary bladder cancer	0.000609	0.000949	CcSEcCtD
Granisetron—Chills—Epirubicin—urinary bladder cancer	0.000603	0.000939	CcSEcCtD
Granisetron—Pruritus—Etoposide—urinary bladder cancer	0.000602	0.000938	CcSEcCtD
Granisetron—CYP3A4—Biological oxidations—GSTZ1—urinary bladder cancer	0.000602	0.00311	CbGpPWpGaD
Granisetron—Arrhythmia—Epirubicin—urinary bladder cancer	0.0006	0.000935	CcSEcCtD
Granisetron—Visual impairment—Doxorubicin—urinary bladder cancer	0.000599	0.000933	CcSEcCtD
Granisetron—CYP3A4—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000594	0.00307	CbGpPWpGaD
Granisetron—Alopecia—Epirubicin—urinary bladder cancer	0.000593	0.000925	CcSEcCtD
Granisetron—Nausea—Gemcitabine—urinary bladder cancer	0.000592	0.000923	CcSEcCtD
Granisetron—Vomiting—Cisplatin—urinary bladder cancer	0.000591	0.00092	CcSEcCtD
Granisetron—Rash—Cisplatin—urinary bladder cancer	0.000586	0.000913	CcSEcCtD
Granisetron—Dermatitis—Cisplatin—urinary bladder cancer	0.000585	0.000912	CcSEcCtD
Granisetron—Malnutrition—Epirubicin—urinary bladder cancer	0.000585	0.000911	CcSEcCtD
Granisetron—Diarrhoea—Etoposide—urinary bladder cancer	0.000582	0.000907	CcSEcCtD
Granisetron—Nausea—Fluorouracil—urinary bladder cancer	0.000582	0.000907	CcSEcCtD
Granisetron—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.00058	0.000903	CcSEcCtD
Granisetron—Anaemia—Methotrexate—urinary bladder cancer	0.000577	0.0009	CcSEcCtD
Granisetron—Flushing—Doxorubicin—urinary bladder cancer	0.000577	0.000899	CcSEcCtD
Granisetron—Flatulence—Epirubicin—urinary bladder cancer	0.000576	0.000898	CcSEcCtD
Granisetron—Tension—Epirubicin—urinary bladder cancer	0.000574	0.000894	CcSEcCtD
Granisetron—Dysgeusia—Epirubicin—urinary bladder cancer	0.000572	0.000892	CcSEcCtD
Granisetron—CYP3A4—Biological oxidations—GSTO2—urinary bladder cancer	0.000571	0.00295	CbGpPWpGaD
Granisetron—CYP3A4—Biological oxidations—NAT1—urinary bladder cancer	0.000571	0.00295	CbGpPWpGaD
Granisetron—HTR3A—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.00057	0.00294	CbGpPWpGaD
Granisetron—Nervousness—Epirubicin—urinary bladder cancer	0.000568	0.000885	CcSEcCtD
Granisetron—Angiopathy—Doxorubicin—urinary bladder cancer	0.000564	0.000878	CcSEcCtD
Granisetron—Malaise—Methotrexate—urinary bladder cancer	0.000563	0.000878	CcSEcCtD
Granisetron—Dizziness—Etoposide—urinary bladder cancer	0.000563	0.000877	CcSEcCtD
Granisetron—CYP3A4—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000563	0.00291	CbGpPWpGaD
Granisetron—Vertigo—Methotrexate—urinary bladder cancer	0.000561	0.000875	CcSEcCtD
Granisetron—Leukopenia—Methotrexate—urinary bladder cancer	0.000559	0.000871	CcSEcCtD
Granisetron—Chills—Doxorubicin—urinary bladder cancer	0.000558	0.000869	CcSEcCtD
Granisetron—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000555	0.000865	CcSEcCtD
Granisetron—Nausea—Cisplatin—urinary bladder cancer	0.000552	0.00086	CcSEcCtD
Granisetron—Alopecia—Doxorubicin—urinary bladder cancer	0.000549	0.000856	CcSEcCtD
Granisetron—Cough—Methotrexate—urinary bladder cancer	0.000545	0.000849	CcSEcCtD
Granisetron—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000542	0.000845	CcSEcCtD
Granisetron—Vomiting—Etoposide—urinary bladder cancer	0.000541	0.000843	CcSEcCtD
Granisetron—Malnutrition—Doxorubicin—urinary bladder cancer	0.000541	0.000843	CcSEcCtD
Granisetron—Anaemia—Epirubicin—urinary bladder cancer	0.00054	0.000842	CcSEcCtD
Granisetron—HTR3A—SIDS Susceptibility Pathways—EP300—urinary bladder cancer	0.000538	0.00278	CbGpPWpGaD
Granisetron—CYP3A5—Biological oxidations—HPGDS—urinary bladder cancer	0.000538	0.00278	CbGpPWpGaD
Granisetron—Agitation—Epirubicin—urinary bladder cancer	0.000537	0.000837	CcSEcCtD
Granisetron—Rash—Etoposide—urinary bladder cancer	0.000537	0.000836	CcSEcCtD
Granisetron—Dermatitis—Etoposide—urinary bladder cancer	0.000536	0.000835	CcSEcCtD
Granisetron—Headache—Etoposide—urinary bladder cancer	0.000533	0.000831	CcSEcCtD
Granisetron—Flatulence—Doxorubicin—urinary bladder cancer	0.000533	0.000831	CcSEcCtD
Granisetron—Arthralgia—Methotrexate—urinary bladder cancer	0.000532	0.000829	CcSEcCtD
Granisetron—Chest pain—Methotrexate—urinary bladder cancer	0.000532	0.000829	CcSEcCtD
Granisetron—Tension—Doxorubicin—urinary bladder cancer	0.000531	0.000827	CcSEcCtD
Granisetron—Dysgeusia—Doxorubicin—urinary bladder cancer	0.00053	0.000825	CcSEcCtD
Granisetron—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000528	0.000823	CcSEcCtD
Granisetron—Malaise—Epirubicin—urinary bladder cancer	0.000527	0.000821	CcSEcCtD
Granisetron—Discomfort—Methotrexate—urinary bladder cancer	0.000525	0.000819	CcSEcCtD
Granisetron—Nervousness—Doxorubicin—urinary bladder cancer	0.000525	0.000819	CcSEcCtD
Granisetron—Vertigo—Epirubicin—urinary bladder cancer	0.000525	0.000818	CcSEcCtD
Granisetron—Syncope—Epirubicin—urinary bladder cancer	0.000524	0.000817	CcSEcCtD
Granisetron—Leukopenia—Epirubicin—urinary bladder cancer	0.000523	0.000815	CcSEcCtD
Granisetron—CYP3A4—Biological oxidations—UGT2B7—urinary bladder cancer	0.000522	0.0027	CbGpPWpGaD
Granisetron—CYP3A5—Biological oxidations—GSTT1—urinary bladder cancer	0.000522	0.00269	CbGpPWpGaD
Granisetron—Palpitations—Epirubicin—urinary bladder cancer	0.000517	0.000805	CcSEcCtD
Granisetron—CYP3A4—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000515	0.00266	CbGpPWpGaD
Granisetron—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000514	0.000801	CcSEcCtD
Granisetron—Cough—Epirubicin—urinary bladder cancer	0.00051	0.000795	CcSEcCtD
Granisetron—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.00051	0.000794	CcSEcCtD
Granisetron—CYP1A1—Aryl Hydrocarbon Receptor—PTGS2—urinary bladder cancer	0.000508	0.00262	CbGpPWpGaD
Granisetron—CYP1A1—Biological oxidations—HPGDS—urinary bladder cancer	0.000508	0.00262	CbGpPWpGaD
Granisetron—Infection—Methotrexate—urinary bladder cancer	0.000507	0.000789	CcSEcCtD
Granisetron—Nausea—Etoposide—urinary bladder cancer	0.000506	0.000788	CcSEcCtD
Granisetron—Hypertension—Epirubicin—urinary bladder cancer	0.000505	0.000786	CcSEcCtD
Granisetron—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000502	0.000782	CcSEcCtD
Granisetron—Nervous system disorder—Methotrexate—urinary bladder cancer	0.0005	0.000779	CcSEcCtD
Granisetron—Anaemia—Doxorubicin—urinary bladder cancer	0.0005	0.000779	CcSEcCtD
Granisetron—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000499	0.000778	CcSEcCtD
Granisetron—Chest pain—Epirubicin—urinary bladder cancer	0.000498	0.000776	CcSEcCtD
Granisetron—Arthralgia—Epirubicin—urinary bladder cancer	0.000498	0.000776	CcSEcCtD
Granisetron—Agitation—Doxorubicin—urinary bladder cancer	0.000497	0.000775	CcSEcCtD
Granisetron—Anxiety—Epirubicin—urinary bladder cancer	0.000496	0.000773	CcSEcCtD
Granisetron—Skin disorder—Methotrexate—urinary bladder cancer	0.000495	0.000772	CcSEcCtD
Granisetron—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000494	0.00077	CcSEcCtD
Granisetron—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000493	0.000768	CcSEcCtD
Granisetron—CYP1A1—Biological oxidations—GSTT1—urinary bladder cancer	0.000493	0.00254	CbGpPWpGaD
Granisetron—Discomfort—Epirubicin—urinary bladder cancer	0.000492	0.000766	CcSEcCtD
Granisetron—Malaise—Doxorubicin—urinary bladder cancer	0.000488	0.00076	CcSEcCtD
Granisetron—Dry mouth—Epirubicin—urinary bladder cancer	0.000487	0.000758	CcSEcCtD
Granisetron—Vertigo—Doxorubicin—urinary bladder cancer	0.000486	0.000757	CcSEcCtD
Granisetron—Syncope—Doxorubicin—urinary bladder cancer	0.000485	0.000756	CcSEcCtD
Granisetron—Leukopenia—Doxorubicin—urinary bladder cancer	0.000484	0.000754	CcSEcCtD
Granisetron—CYP2D6—Biological oxidations—NAT2—urinary bladder cancer	0.000478	0.00247	CbGpPWpGaD
Granisetron—Palpitations—Doxorubicin—urinary bladder cancer	0.000478	0.000745	CcSEcCtD
Granisetron—Oedema—Epirubicin—urinary bladder cancer	0.000477	0.000743	CcSEcCtD
Granisetron—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000477	0.000743	CcSEcCtD
Granisetron—Hypotension—Methotrexate—urinary bladder cancer	0.000476	0.000742	CcSEcCtD
Granisetron—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000475	0.000741	CcSEcCtD
Granisetron—CYP1A1—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000475	0.00245	CbGpPWpGaD
Granisetron—Infection—Epirubicin—urinary bladder cancer	0.000474	0.000739	CcSEcCtD
Granisetron—Cough—Doxorubicin—urinary bladder cancer	0.000472	0.000735	CcSEcCtD
Granisetron—CYP2D6—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000472	0.00244	CbGpPWpGaD
Granisetron—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL2—urinary bladder cancer	0.000471	0.00243	CbGpPWpGaD
Granisetron—CYP3A4—Biological oxidations—CYP4B1—urinary bladder cancer	0.00047	0.00243	CbGpPWpGaD
Granisetron—Shock—Epirubicin—urinary bladder cancer	0.000469	0.000731	CcSEcCtD
Granisetron—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000468	0.000729	CcSEcCtD
Granisetron—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000467	0.000728	CcSEcCtD
Granisetron—Hypertension—Doxorubicin—urinary bladder cancer	0.000467	0.000728	CcSEcCtD
Granisetron—Tachycardia—Epirubicin—urinary bladder cancer	0.000466	0.000726	CcSEcCtD
Granisetron—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000464	0.000724	CcSEcCtD
Granisetron—CYP3A4—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000463	0.00239	CbGpPWpGaD
Granisetron—Skin disorder—Epirubicin—urinary bladder cancer	0.000463	0.000722	CcSEcCtD
Granisetron—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000461	0.000719	CcSEcCtD
Granisetron—Insomnia—Methotrexate—urinary bladder cancer	0.000461	0.000719	CcSEcCtD
Granisetron—Chest pain—Doxorubicin—urinary bladder cancer	0.000461	0.000718	CcSEcCtD
Granisetron—Arthralgia—Doxorubicin—urinary bladder cancer	0.000461	0.000718	CcSEcCtD
Granisetron—Anxiety—Doxorubicin—urinary bladder cancer	0.000459	0.000715	CcSEcCtD
Granisetron—Paraesthesia—Methotrexate—urinary bladder cancer	0.000458	0.000713	CcSEcCtD
Granisetron—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000457	0.000713	CcSEcCtD
Granisetron—Discomfort—Doxorubicin—urinary bladder cancer	0.000455	0.000709	CcSEcCtD
Granisetron—Dyspnoea—Methotrexate—urinary bladder cancer	0.000455	0.000708	CcSEcCtD
Granisetron—Somnolence—Methotrexate—urinary bladder cancer	0.000453	0.000706	CcSEcCtD
Granisetron—Dry mouth—Doxorubicin—urinary bladder cancer	0.00045	0.000702	CcSEcCtD
Granisetron—Dyspepsia—Methotrexate—urinary bladder cancer	0.000449	0.000699	CcSEcCtD
Granisetron—CYP1A1—PPARA activates gene expression—NCOR1—urinary bladder cancer	0.000449	0.00232	CbGpPWpGaD
Granisetron—Hypotension—Epirubicin—urinary bladder cancer	0.000446	0.000695	CcSEcCtD
Granisetron—CYP1A1—Aryl Hydrocarbon Receptor—CDKN1A—urinary bladder cancer	0.000444	0.00229	CbGpPWpGaD
Granisetron—Decreased appetite—Methotrexate—urinary bladder cancer	0.000443	0.000691	CcSEcCtD
Granisetron—Oedema—Doxorubicin—urinary bladder cancer	0.000441	0.000688	CcSEcCtD
Granisetron—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000441	0.000688	CcSEcCtD
Granisetron—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.00044	0.000686	CcSEcCtD
Granisetron—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—NCOR1—urinary bladder cancer	0.000439	0.00227	CbGpPWpGaD
Granisetron—Infection—Doxorubicin—urinary bladder cancer	0.000439	0.000683	CcSEcCtD
Granisetron—HTR3A—SIDS Susceptibility Pathways—TNF—urinary bladder cancer	0.000436	0.00225	CbGpPWpGaD
Granisetron—Pain—Methotrexate—urinary bladder cancer	0.000436	0.000679	CcSEcCtD
Granisetron—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000435	0.000677	CcSEcCtD
Granisetron—Shock—Doxorubicin—urinary bladder cancer	0.000434	0.000677	CcSEcCtD
Granisetron—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000433	0.000675	CcSEcCtD
Granisetron—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000432	0.000674	CcSEcCtD
Granisetron—Insomnia—Epirubicin—urinary bladder cancer	0.000432	0.000672	CcSEcCtD
Granisetron—Tachycardia—Doxorubicin—urinary bladder cancer	0.000431	0.000671	CcSEcCtD
Granisetron—Skin disorder—Doxorubicin—urinary bladder cancer	0.000429	0.000668	CcSEcCtD
Granisetron—Paraesthesia—Epirubicin—urinary bladder cancer	0.000428	0.000668	CcSEcCtD
Granisetron—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000427	0.000665	CcSEcCtD
Granisetron—Dyspnoea—Epirubicin—urinary bladder cancer	0.000425	0.000663	CcSEcCtD
Granisetron—Somnolence—Epirubicin—urinary bladder cancer	0.000424	0.000661	CcSEcCtD
Granisetron—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EP300—urinary bladder cancer	0.000423	0.00218	CbGpPWpGaD
Granisetron—CYP1A1—Aryl Hydrocarbon Receptor—EP300—urinary bladder cancer	0.000423	0.00218	CbGpPWpGaD
Granisetron—Feeling abnormal—Methotrexate—urinary bladder cancer	0.00042	0.000655	CcSEcCtD
Granisetron—Dyspepsia—Epirubicin—urinary bladder cancer	0.00042	0.000654	CcSEcCtD
Granisetron—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000417	0.00065	CcSEcCtD
Granisetron—Decreased appetite—Epirubicin—urinary bladder cancer	0.000415	0.000646	CcSEcCtD
Granisetron—Hypotension—Doxorubicin—urinary bladder cancer	0.000413	0.000643	CcSEcCtD
Granisetron—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000412	0.000642	CcSEcCtD
Granisetron—CYP1A1—Aryl Hydrocarbon Receptor Pathway—SRC—urinary bladder cancer	0.000411	0.00212	CbGpPWpGaD
Granisetron—CYP1A1—Aryl Hydrocarbon Receptor—SRC—urinary bladder cancer	0.000411	0.00212	CbGpPWpGaD
Granisetron—Constipation—Epirubicin—urinary bladder cancer	0.000408	0.000636	CcSEcCtD
Granisetron—Pain—Epirubicin—urinary bladder cancer	0.000408	0.000636	CcSEcCtD
Granisetron—Urticaria—Methotrexate—urinary bladder cancer	0.000405	0.000631	CcSEcCtD
Granisetron—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000405	0.00209	CbGpPWpGaD
Granisetron—Body temperature increased—Methotrexate—urinary bladder cancer	0.000403	0.000628	CcSEcCtD
Granisetron—Abdominal pain—Methotrexate—urinary bladder cancer	0.000403	0.000628	CcSEcCtD
Granisetron—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000402	0.000627	CcSEcCtD
Granisetron—Insomnia—Doxorubicin—urinary bladder cancer	0.000399	0.000622	CcSEcCtD
Granisetron—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000396	0.000618	CcSEcCtD
Granisetron—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000394	0.000613	CcSEcCtD
Granisetron—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000393	0.000613	CcSEcCtD
Granisetron—Somnolence—Doxorubicin—urinary bladder cancer	0.000392	0.000612	CcSEcCtD
Granisetron—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.00039	0.000608	CcSEcCtD
Granisetron—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000389	0.000606	CcSEcCtD
Granisetron—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000384	0.000598	CcSEcCtD
Granisetron—CYP2D6—Biological oxidations—HPGDS—urinary bladder cancer	0.000382	0.00197	CbGpPWpGaD
Granisetron—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000381	0.000594	CcSEcCtD
Granisetron—Urticaria—Epirubicin—urinary bladder cancer	0.000379	0.000591	CcSEcCtD
Granisetron—Pain—Doxorubicin—urinary bladder cancer	0.000378	0.000588	CcSEcCtD
Granisetron—Constipation—Doxorubicin—urinary bladder cancer	0.000378	0.000588	CcSEcCtD
Granisetron—Abdominal pain—Epirubicin—urinary bladder cancer	0.000377	0.000588	CcSEcCtD
Granisetron—Body temperature increased—Epirubicin—urinary bladder cancer	0.000377	0.000588	CcSEcCtD
Granisetron—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000376	0.000585	CcSEcCtD
Granisetron—CYP2D6—Biological oxidations—GSTT1—urinary bladder cancer	0.000371	0.00192	CbGpPWpGaD
Granisetron—CYP1A1—Aryl Hydrocarbon Receptor—MYC—urinary bladder cancer	0.000368	0.0019	CbGpPWpGaD
Granisetron—CYP1A1—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000367	0.00189	CbGpPWpGaD
Granisetron—Asthenia—Methotrexate—urinary bladder cancer	0.000366	0.00057	CcSEcCtD
Granisetron—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000364	0.000567	CcSEcCtD
Granisetron—CYP3A5—Biological oxidations—GSTP1—urinary bladder cancer	0.000361	0.00187	CbGpPWpGaD
Granisetron—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000361	0.000562	CcSEcCtD
Granisetron—Pruritus—Methotrexate—urinary bladder cancer	0.000361	0.000562	CcSEcCtD
Granisetron—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—urinary bladder cancer	0.00036	0.00186	CbGpPWpGaD
Granisetron—CYP1A1—Aryl Hydrocarbon Receptor—EGFR—urinary bladder cancer	0.00036	0.00186	CbGpPWpGaD
Granisetron—CYP3A5—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000357	0.00184	CbGpPWpGaD
Granisetron—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000352	0.000548	CcSEcCtD
Granisetron—Urticaria—Doxorubicin—urinary bladder cancer	0.000351	0.000546	CcSEcCtD
Granisetron—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000349	0.000544	CcSEcCtD
Granisetron—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000349	0.000544	CcSEcCtD
Granisetron—Diarrhoea—Methotrexate—urinary bladder cancer	0.000349	0.000544	CcSEcCtD
Granisetron—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—urinary bladder cancer	0.000343	0.00177	CbGpPWpGaD
Granisetron—CYP1A1—Aryl Hydrocarbon Receptor—TNF—urinary bladder cancer	0.000343	0.00177	CbGpPWpGaD
Granisetron—Asthenia—Epirubicin—urinary bladder cancer	0.000342	0.000533	CcSEcCtD
Granisetron—CYP1A1—Biological oxidations—GSTP1—urinary bladder cancer	0.000342	0.00176	CbGpPWpGaD
Granisetron—CYP1A1—Aryl Hydrocarbon Receptor—KRAS—urinary bladder cancer	0.00034	0.00176	CbGpPWpGaD
Granisetron—Pruritus—Epirubicin—urinary bladder cancer	0.000338	0.000526	CcSEcCtD
Granisetron—Dizziness—Methotrexate—urinary bladder cancer	0.000337	0.000525	CcSEcCtD
Granisetron—CYP1A1—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000337	0.00174	CbGpPWpGaD
Granisetron—CYP3A5—Biological oxidations—GSTM1—urinary bladder cancer	0.000332	0.00172	CbGpPWpGaD
Granisetron—CYP3A5—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000328	0.00169	CbGpPWpGaD
Granisetron—Diarrhoea—Epirubicin—urinary bladder cancer	0.000326	0.000509	CcSEcCtD
Granisetron—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000325	0.000507	CcSEcCtD
Granisetron—Vomiting—Methotrexate—urinary bladder cancer	0.000324	0.000505	CcSEcCtD
Granisetron—CYP1A1—PPARA activates gene expression—PPARG—urinary bladder cancer	0.000322	0.00166	CbGpPWpGaD
Granisetron—Rash—Methotrexate—urinary bladder cancer	0.000321	0.000501	CcSEcCtD
Granisetron—Dermatitis—Methotrexate—urinary bladder cancer	0.000321	0.0005	CcSEcCtD
Granisetron—Headache—Methotrexate—urinary bladder cancer	0.000319	0.000498	CcSEcCtD
Granisetron—Asthenia—Doxorubicin—urinary bladder cancer	0.000317	0.000494	CcSEcCtD
Granisetron—Dizziness—Epirubicin—urinary bladder cancer	0.000316	0.000492	CcSEcCtD
Granisetron—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—urinary bladder cancer	0.000315	0.00163	CbGpPWpGaD
Granisetron—CYP1A1—Biological oxidations—GSTM1—urinary bladder cancer	0.000314	0.00162	CbGpPWpGaD
Granisetron—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	0.000313	0.00161	CbGpPWpGaD
Granisetron—Pruritus—Doxorubicin—urinary bladder cancer	0.000312	0.000487	CcSEcCtD
Granisetron—CYP1A1—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.00031	0.0016	CbGpPWpGaD
Granisetron—CYP1A1—PPARA activates gene expression—CREBBP—urinary bladder cancer	0.000309	0.0016	CbGpPWpGaD
Granisetron—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000308	0.00159	CbGpPWpGaD
Granisetron—Vomiting—Epirubicin—urinary bladder cancer	0.000303	0.000473	CcSEcCtD
Granisetron—Nausea—Methotrexate—urinary bladder cancer	0.000303	0.000472	CcSEcCtD
Granisetron—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—NCOR1—urinary bladder cancer	0.000303	0.00156	CbGpPWpGaD
Granisetron—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CREBBP—urinary bladder cancer	0.000302	0.00156	CbGpPWpGaD
Granisetron—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000302	0.000471	CcSEcCtD
Granisetron—Rash—Epirubicin—urinary bladder cancer	0.000301	0.000469	CcSEcCtD
Granisetron—Dermatitis—Epirubicin—urinary bladder cancer	0.000301	0.000468	CcSEcCtD
Granisetron—Headache—Epirubicin—urinary bladder cancer	0.000299	0.000466	CcSEcCtD
Granisetron—Dizziness—Doxorubicin—urinary bladder cancer	0.000292	0.000455	CcSEcCtD
Granisetron—CYP1A1—Aryl Hydrocarbon Receptor—HRAS—urinary bladder cancer	0.000289	0.00149	CbGpPWpGaD
Granisetron—Nausea—Epirubicin—urinary bladder cancer	0.000283	0.000442	CcSEcCtD
Granisetron—Vomiting—Doxorubicin—urinary bladder cancer	0.000281	0.000437	CcSEcCtD
Granisetron—Rash—Doxorubicin—urinary bladder cancer	0.000278	0.000434	CcSEcCtD
Granisetron—Dermatitis—Doxorubicin—urinary bladder cancer	0.000278	0.000433	CcSEcCtD
Granisetron—Headache—Doxorubicin—urinary bladder cancer	0.000277	0.000431	CcSEcCtD
Granisetron—HTR3A—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	0.000267	0.00138	CbGpPWpGaD
Granisetron—Nausea—Doxorubicin—urinary bladder cancer	0.000262	0.000409	CcSEcCtD
Granisetron—CYP2D6—Biological oxidations—GSTP1—urinary bladder cancer	0.000257	0.00133	CbGpPWpGaD
Granisetron—CYP2D6—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000254	0.00131	CbGpPWpGaD
Granisetron—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	0.00025	0.00129	CbGpPWpGaD
Granisetron—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	0.000242	0.00125	CbGpPWpGaD
Granisetron—CYP2D6—Biological oxidations—GSTM1—urinary bladder cancer	0.000236	0.00122	CbGpPWpGaD
Granisetron—CYP2D6—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000233	0.0012	CbGpPWpGaD
Granisetron—CYP3A5—Metabolism—GSTZ1—urinary bladder cancer	0.000221	0.00114	CbGpPWpGaD
Granisetron—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—urinary bladder cancer	0.000217	0.00112	CbGpPWpGaD
Granisetron—CYP1A1—PPARA activates gene expression—EP300—urinary bladder cancer	0.00021	0.00109	CbGpPWpGaD
Granisetron—CYP3A5—Metabolism—GSTO2—urinary bladder cancer	0.00021	0.00108	CbGpPWpGaD
Granisetron—CYP3A5—Metabolism—NAT1—urinary bladder cancer	0.00021	0.00108	CbGpPWpGaD
Granisetron—CYP1A1—Metabolism—GSTZ1—urinary bladder cancer	0.000209	0.00108	CbGpPWpGaD
Granisetron—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—CREBBP—urinary bladder cancer	0.000208	0.00108	CbGpPWpGaD
Granisetron—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—urinary bladder cancer	0.000206	0.00106	CbGpPWpGaD
Granisetron—CYP1A1—Metabolism—GSTO2—urinary bladder cancer	0.000198	0.00102	CbGpPWpGaD
Granisetron—CYP1A1—Metabolism—NAT1—urinary bladder cancer	0.000198	0.00102	CbGpPWpGaD
Granisetron—CYP1A1—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.000195	0.00101	CbGpPWpGaD
Granisetron—CYP3A5—Metabolism—UGT2B7—urinary bladder cancer	0.000192	0.000992	CbGpPWpGaD
Granisetron—CYP1A1—Metabolism—UGT2B7—urinary bladder cancer	0.000181	0.000937	CbGpPWpGaD
Granisetron—CYP3A5—Metabolism—CYP4B1—urinary bladder cancer	0.000173	0.000893	CbGpPWpGaD
Granisetron—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	0.000168	0.000868	CbGpPWpGaD
Granisetron—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000166	0.000856	CbGpPWpGaD
Granisetron—CYP1A1—Metabolism—CYP4B1—urinary bladder cancer	0.000163	0.000843	CbGpPWpGaD
Granisetron—CYP3A5—Metabolism—SLC19A1—urinary bladder cancer	0.000163	0.000843	CbGpPWpGaD
Granisetron—CYP3A5—Metabolism—PRSS3—urinary bladder cancer	0.000159	0.000822	CbGpPWpGaD
Granisetron—CYP2D6—Metabolism—GSTZ1—urinary bladder cancer	0.000157	0.000813	CbGpPWpGaD
Granisetron—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	0.000154	0.000798	CbGpPWpGaD
Granisetron—CYP1A1—Metabolism—SLC19A1—urinary bladder cancer	0.000154	0.000797	CbGpPWpGaD
Granisetron—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000152	0.000787	CbGpPWpGaD
Granisetron—CYP1A1—Metabolism—PRSS3—urinary bladder cancer	0.00015	0.000776	CbGpPWpGaD
Granisetron—CYP2D6—Metabolism—NAT1—urinary bladder cancer	0.000149	0.000771	CbGpPWpGaD
Granisetron—CYP2D6—Metabolism—GSTO2—urinary bladder cancer	0.000149	0.000771	CbGpPWpGaD
Granisetron—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—urinary bladder cancer	0.000142	0.000733	CbGpPWpGaD
Granisetron—CYP2D6—Metabolism—UGT2B7—urinary bladder cancer	0.000137	0.000705	CbGpPWpGaD
Granisetron—CYP3A5—Metabolism—TYMP—urinary bladder cancer	0.000127	0.000657	CbGpPWpGaD
Granisetron—CYP2D6—Metabolism—CYP4B1—urinary bladder cancer	0.000123	0.000635	CbGpPWpGaD
Granisetron—CYP1A1—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	0.000121	0.000622	CbGpPWpGaD
Granisetron—CYP1A1—Metabolism—TYMP—urinary bladder cancer	0.00012	0.000621	CbGpPWpGaD
Granisetron—CYP2D6—Metabolism—SLC19A1—urinary bladder cancer	0.000116	0.000599	CbGpPWpGaD
Granisetron—CYP1A1—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	0.000115	0.000596	CbGpPWpGaD
Granisetron—CYP3A5—Metabolism—NAT2—urinary bladder cancer	0.000115	0.000594	CbGpPWpGaD
Granisetron—CYP2D6—Metabolism—PRSS3—urinary bladder cancer	0.000113	0.000584	CbGpPWpGaD
Granisetron—CYP1A1—Metabolism—NAT2—urinary bladder cancer	0.000109	0.000561	CbGpPWpGaD
Granisetron—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	0.000103	0.000532	CbGpPWpGaD
Granisetron—CYP3A5—Metabolism—RRM2—urinary bladder cancer	9.93e-05	0.000513	CbGpPWpGaD
Granisetron—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	9.76e-05	0.000504	CbGpPWpGaD
Granisetron—CYP3A4—Metabolism—NAT1—urinary bladder cancer	9.76e-05	0.000504	CbGpPWpGaD
Granisetron—CYP1A1—Metabolism—RRM2—urinary bladder cancer	9.38e-05	0.000484	CbGpPWpGaD
Granisetron—CYP3A5—Metabolism—HPGDS—urinary bladder cancer	9.2e-05	0.000475	CbGpPWpGaD
Granisetron—CYP3A5—Metabolism—ENO2—urinary bladder cancer	9.2e-05	0.000475	CbGpPWpGaD
Granisetron—CYP2D6—Metabolism—TYMP—urinary bladder cancer	9.04e-05	0.000467	CbGpPWpGaD
Granisetron—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	8.93e-05	0.000461	CbGpPWpGaD
Granisetron—CYP3A5—Metabolism—GSTT1—urinary bladder cancer	8.92e-05	0.000461	CbGpPWpGaD
Granisetron—CYP1A1—Metabolism—HPGDS—urinary bladder cancer	8.69e-05	0.000449	CbGpPWpGaD
Granisetron—CYP1A1—Metabolism—ENO2—urinary bladder cancer	8.69e-05	0.000449	CbGpPWpGaD
Granisetron—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	8.64e-05	0.000446	CbGpPWpGaD
Granisetron—CYP1A1—Metabolism—GSTT1—urinary bladder cancer	8.43e-05	0.000435	CbGpPWpGaD
Granisetron—CYP1A1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	8.3e-05	0.000428	CbGpPWpGaD
Granisetron—CYP2D6—Metabolism—NAT2—urinary bladder cancer	8.18e-05	0.000422	CbGpPWpGaD
Granisetron—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	8.04e-05	0.000415	CbGpPWpGaD
Granisetron—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	7.59e-05	0.000392	CbGpPWpGaD
Granisetron—CYP3A5—Metabolism—NQO1—urinary bladder cancer	7.41e-05	0.000383	CbGpPWpGaD
Granisetron—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	7.4e-05	0.000382	CbGpPWpGaD
Granisetron—CYP2D6—Metabolism—RRM2—urinary bladder cancer	7.06e-05	0.000365	CbGpPWpGaD
Granisetron—CYP1A1—Metabolism—NQO1—urinary bladder cancer	7e-05	0.000362	CbGpPWpGaD
Granisetron—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	6.79e-05	0.000351	CbGpPWpGaD
Granisetron—CYP2D6—Metabolism—ENO2—urinary bladder cancer	6.54e-05	0.000338	CbGpPWpGaD
Granisetron—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	6.54e-05	0.000338	CbGpPWpGaD
Granisetron—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	6.34e-05	0.000328	CbGpPWpGaD
Granisetron—CYP3A5—Metabolism—GSTP1—urinary bladder cancer	6.18e-05	0.000319	CbGpPWpGaD
Granisetron—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	5.93e-05	0.000306	CbGpPWpGaD
Granisetron—CYP3A4—Metabolism—TYMP—urinary bladder cancer	5.91e-05	0.000305	CbGpPWpGaD
Granisetron—CYP1A1—Metabolism—GSTP1—urinary bladder cancer	5.84e-05	0.000302	CbGpPWpGaD
Granisetron—CYP3A5—Metabolism—TYMS—urinary bladder cancer	5.75e-05	0.000297	CbGpPWpGaD
Granisetron—CYP3A5—Metabolism—GSTM1—urinary bladder cancer	5.68e-05	0.000293	CbGpPWpGaD
Granisetron—CYP3A5—Metabolism—NCOR1—urinary bladder cancer	5.68e-05	0.000293	CbGpPWpGaD
Granisetron—CYP1A1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	5.65e-05	0.000292	CbGpPWpGaD
Granisetron—CYP3A5—Metabolism—GPX1—urinary bladder cancer	5.44e-05	0.000281	CbGpPWpGaD
Granisetron—CYP1A1—Metabolism—TYMS—urinary bladder cancer	5.43e-05	0.00028	CbGpPWpGaD
Granisetron—CYP1A1—Metabolism—GSTM1—urinary bladder cancer	5.37e-05	0.000277	CbGpPWpGaD
Granisetron—CYP1A1—Metabolism—NCOR1—urinary bladder cancer	5.37e-05	0.000277	CbGpPWpGaD
Granisetron—CYP3A4—Metabolism—NAT2—urinary bladder cancer	5.35e-05	0.000276	CbGpPWpGaD
Granisetron—CYP3A5—Metabolism—ERCC2—urinary bladder cancer	5.34e-05	0.000276	CbGpPWpGaD
Granisetron—CYP2D6—Metabolism—NQO1—urinary bladder cancer	5.27e-05	0.000272	CbGpPWpGaD
Granisetron—CYP1A1—Metabolism—GPX1—urinary bladder cancer	5.14e-05	0.000265	CbGpPWpGaD
Granisetron—CYP1A1—Metabolism—ERCC2—urinary bladder cancer	5.05e-05	0.000261	CbGpPWpGaD
Granisetron—CYP3A5—Metabolism—MTHFR—urinary bladder cancer	5.02e-05	0.000259	CbGpPWpGaD
Granisetron—CYP1A1—Metabolism—MTHFR—urinary bladder cancer	4.74e-05	0.000245	CbGpPWpGaD
Granisetron—CYP3A4—Metabolism—RRM2—urinary bladder cancer	4.62e-05	0.000238	CbGpPWpGaD
Granisetron—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	4.4e-05	0.000227	CbGpPWpGaD
Granisetron—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	4.27e-05	0.000221	CbGpPWpGaD
Granisetron—CYP3A4—Metabolism—ENO2—urinary bladder cancer	4.27e-05	0.000221	CbGpPWpGaD
Granisetron—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	4.15e-05	0.000214	CbGpPWpGaD
Granisetron—CYP2D6—Metabolism—TYMS—urinary bladder cancer	4.09e-05	0.000211	CbGpPWpGaD
Granisetron—CYP3A5—Metabolism—PPARG—urinary bladder cancer	4.07e-05	0.00021	CbGpPWpGaD
Granisetron—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	4.04e-05	0.000209	CbGpPWpGaD
Granisetron—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	4.04e-05	0.000209	CbGpPWpGaD
Granisetron—CYP3A5—Metabolism—CREBBP—urinary bladder cancer	3.91e-05	0.000202	CbGpPWpGaD
Granisetron—CYP2D6—Metabolism—GPX1—urinary bladder cancer	3.87e-05	0.0002	CbGpPWpGaD
Granisetron—CYP1A1—Metabolism—PPARG—urinary bladder cancer	3.85e-05	0.000199	CbGpPWpGaD
Granisetron—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	3.8e-05	0.000196	CbGpPWpGaD
Granisetron—CYP1A1—Metabolism—CREBBP—urinary bladder cancer	3.69e-05	0.000191	CbGpPWpGaD
Granisetron—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	3.57e-05	0.000184	CbGpPWpGaD
Granisetron—CYP3A4—Metabolism—NQO1—urinary bladder cancer	3.45e-05	0.000178	CbGpPWpGaD
Granisetron—CYP3A5—Metabolism—PTGS2—urinary bladder cancer	3.2e-05	0.000165	CbGpPWpGaD
Granisetron—CYP1A1—Metabolism—PTGS2—urinary bladder cancer	3.03e-05	0.000156	CbGpPWpGaD
Granisetron—CYP2D6—Metabolism—PPARG—urinary bladder cancer	2.89e-05	0.00015	CbGpPWpGaD
Granisetron—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	2.87e-05	0.000148	CbGpPWpGaD
Granisetron—CYP3A5—Metabolism—PTEN—urinary bladder cancer	2.79e-05	0.000144	CbGpPWpGaD
Granisetron—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	2.78e-05	0.000144	CbGpPWpGaD
Granisetron—CYP3A4—Metabolism—TYMS—urinary bladder cancer	2.67e-05	0.000138	CbGpPWpGaD
Granisetron—CYP3A5—Metabolism—EP300—urinary bladder cancer	2.66e-05	0.000138	CbGpPWpGaD
Granisetron—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	2.64e-05	0.000136	CbGpPWpGaD
Granisetron—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	2.64e-05	0.000136	CbGpPWpGaD
Granisetron—CYP1A1—Metabolism—PTEN—urinary bladder cancer	2.64e-05	0.000136	CbGpPWpGaD
Granisetron—CYP3A4—Metabolism—GPX1—urinary bladder cancer	2.53e-05	0.000131	CbGpPWpGaD
Granisetron—CYP1A1—Metabolism—EP300—urinary bladder cancer	2.52e-05	0.00013	CbGpPWpGaD
Granisetron—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	2.48e-05	0.000128	CbGpPWpGaD
Granisetron—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	2.33e-05	0.000121	CbGpPWpGaD
Granisetron—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	2.28e-05	0.000118	CbGpPWpGaD
Granisetron—CYP2D6—Metabolism—PTEN—urinary bladder cancer	1.99e-05	0.000103	CbGpPWpGaD
Granisetron—CYP2D6—Metabolism—EP300—urinary bladder cancer	1.89e-05	9.78e-05	CbGpPWpGaD
Granisetron—CYP3A4—Metabolism—PPARG—urinary bladder cancer	1.89e-05	9.77e-05	CbGpPWpGaD
Granisetron—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	1.82e-05	9.39e-05	CbGpPWpGaD
Granisetron—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	1.49e-05	7.69e-05	CbGpPWpGaD
Granisetron—CYP3A4—Metabolism—PTEN—urinary bladder cancer	1.3e-05	6.71e-05	CbGpPWpGaD
Granisetron—CYP3A4—Metabolism—EP300—urinary bladder cancer	1.24e-05	6.39e-05	CbGpPWpGaD
